Arca
Skip to content
Tools
Tools

CD33: Myeloid cell surface antigen CD33

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state.

  • Drugs that act on it: 6
  • Approved: 1
  • In phases 1 to 3: 5
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD33, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Antibody-drug conjugate
  • Other

Approved1

  • Gemtuzumab ozogamicin

Phase 32

  • Gemtuzumab
  • Lintuzumab

Phase 22

  • M195
  • Oncolysin m

Phase 11

  • AVE-9633

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody233%
  • Antibody-drug conjugate117%
  • Other350%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Myeloid cell surface antigen CD33 binding agent; the rest name their own mechanism.
Gemtuzumab ozogamicinApprovedPfizerAntibody-drug conjugateBinding agent—25WithdrawnBoxed warning
GemtuzumabPhase 3—AntibodyBinding agent—26—
LintuzumabPhase 3PfizerAntibodyOtherMyeloid cell surface antigen CD33 other1—
M195Phase 2—OtherOtherMyeloid cell surface antigen CD33 other0—
Oncolysin mPhase 2—OtherBinding agent—0—
AVE-9633Phase 1SanofiOtherBinding agent—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaLintuzumabPhase 1Not yet recruitingNational Cancer Institute (NCI)2026-02-20
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)Gemtuzumab ozogamicin, GemtuzumabPhase 2RecruitingNational Cancer Institute (NCI)2025-04-09
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.Gemtuzumab ozogamicin, GemtuzumabPhase 3RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS2024-12-03
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaGemtuzumab ozogamicin, GemtuzumabPhase 1RecruitingM.D. Anderson Cancer Center2024-06-07
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML PatientsGemtuzumab ozogamicin, GemtuzumabPhase 3RecruitingPrincess Maxima Center for Pediatric Oncology2023-08-16
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaGemtuzumab ozogamicin, GemtuzumabPhase 2RecruitingSt. Jude Children's Research Hospital2023-07-21
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLGemtuzumab ozogamicin, GemtuzumabPhase 2RecruitingTechnische Universität Dresden2023-06-15
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AMLGemtuzumab ozogamicin, GemtuzumabPhase 1Not yet recruitingGerman Cancer Research Center2022-12-23
Vyxeos for Induction of Low- or Intermediate-risk.Gemtuzumab ozogamicin, GemtuzumabPhase 2Active, not recruitingShaare Zedek Medical Center2022-10-31

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Alzheimer disease
0.61
Smoking initiation
0.42
Neoplasm
0.40
Acute myeloid leukemia by FAB classification
0.39
Dengue disease
0.37
Parkinson disease
0.37
Neurodegenerative disease
0.35

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1842, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20138, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.